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Abstract
Background. The radiographic evaluation of the response to 
preoperative chemotherapy for bone and soft tissue sarcomas 
is based mostly on the change in primary tumor size before 
and after chemotherapy, as is done for many solid cancers. Its 
prognostic correlation, however, has hardly been validated.
Methods. We conducted a retrospective validation study of 
the Japanese Orthopaedic Association (JOA) radiographic 
response evaluation criteria of preoperative chemotherapy for 
bone and soft tissue sarcomas as a JOA Committee on Mus-
culoskeletal Tumors cooperative study. A total of 125 con-
secutive patients with high-grade bone (n = 77) and soft tissue 
(n = 48) sarcomas treated with neoadjuvant chemotherapy 
and defi nitive surgery in 25 tertiary referral hospitals were 
selected for the study. We investigated the correlation between 
the tumor size-based radiographic response evaluation crite-
ria of preoperative chemotherapy for bone and soft tissue 
sarcomas provided by the JOA Committee on Musculoskele-
tal Tumors (hereafter called the JOA criteria) and the patients’ 
overall survival using the Kaplan-Meier method and the 
log-rank test.
Results. The JOA criteria correlated relatively well with sur-
vival for malignant bone tumors (mostly comprising osteosar-
coma and Ewing’s sarcoma) but not for soft tissue sarcomas, 
suggesting that the tumor size-based radiographic evaluation 
criteria for the response to preoperative chemotherapy in 
patients with soft tissue sarcomas is invalid.
Conclusions. The JOA criteria, based on the change in primary 
tumor size, is valid for malignant bone tumors but invalid for 
soft tissue sarcomas. Other new evaluation modalities of the 
response to preoperative chemotherapy using innovative 
functional imaging techniques are needed for soft tissue 
sarcomas.
Introduction
The multidisciplinary approach, including neoadjuvant 
chemotherapy and wide local excision of primary tumors 
with or without radiation therapy, has dramatically 
improved the prognosis of patients with malignant bone 
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and soft tissue sarcomas, especially osteosarcoma1–3 and 
Ewing’s sarcoma.4–6 Furthermore, the limb-salvage 
procedure is now established as a standard treatment 
modality in this fi eld. To accomplish limb-salvage 
surgery confi dently, it is mandatory to evaluate the 
clinical response of primary tumors to preoperative 
chemotherapy.
We have been using radiographic and histological 
evaluation criteria to estimate the effi cacy of preopera-
tive chemotherapy for bone and soft tissue sarcomas.7,8 
The radiographic response is evaluated based on the 
change in the primary tumor size before and after pre-
operative chemotherapy in the Japanese Orthopaedic 
Association (JOA) evaluation criteria of preoperative 
chemotherapy for bone and soft tissue sarcomas (here-
after called the JOA criteria). This measure is done also 
for many solid cancers using World Health Organiza-
tion (WHO) evaluation criteria or, more recently, the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
in the oncology fi eld worldwide.9 The prognostic signifi -
cance of histological evaluation of response to preop-
erative chemotherapy assessed by the percent ratio of 
treatment-induced tumor necrosis in surgically resected 
tumor specimens has been well proven in patients with 
malignant bone tumors such as osteosarcoma10 and 
Ewing’s sarcoma,11,12 although it is still controversial for 
soft tissue sarcomas.13,14
There is generally no consensus that the radiographic 
evaluation of response to preoperative chemotherapy 
based on the change of tumor size correlates with sur-
vival in patients with bone and soft tissue sarcomas, and 
its prognostic implication has been validated only in a 
retrospective study of 65 patients with soft tissue sarco-
mas.15 Thus, we have conducted a retrospective valida-
tion study of the JOA criteria of preoperative 
chemotherapy for bone and soft tissue sarcomas as a 
cooperative study by the JOA Committee on Musculo-
skeletal Tumors.
Materials and methods
Patients
A total of 125 consecutive patients with high-grade 
bone and soft tissue sarcomas treated with neoadjuvant 
chemotherapy and defi nitive surgery in 25 tertiary 
referral cancer centers or university hospitals between 
January and December in 1997 were selected for the 
current study according to an inquiry conducted by the 
JOA Committee on Musculoskeletal Tumors in 2002. 
The cases included 77 primary malignant bone tumors 
and 48 soft tissue sarcomas.
The patient and tumor characteristics are summa-
rized in Table 1. There were 75 male and 50 female 
Table 1. Patient and tumor characteristics (n = 125)
Bone tumors Soft tissue sarcomas
Characteristic Total or range (n = 77) (n = 48)
Sex (M : F) 75 : 50 46 : 31 29 : 19
Age (years)
 Range (median) 4–75 (25) 4–65 (16) 11–75 (49)
Disease stage at presentation
 Localized (M0) 104 67 37
 Metastatic (M1) 21 10 11
Primary location
Femur 32 Lower extremitya 35
Tibia 19 Upper extremitya 5
Pelvis 11 Trunk 4
Humerus 5 Head and neck 4
Other bones 10b
Histological type
Osteosarcoma 53 MFH 11
Ewing’s sarcoma 11 Liposarcoma 7
MFH 4 Synovial sarcoma 6
Postradiation sarcoma 3 Rhabdomyosarcoma 5
Others 6c MPNST 3
Extraskeletal chondrosarcoma 3
Othersd  13
MFH, malignant fi brous histiocytoma; MPNST, malignant peripheral nerve sheath tumor
a Includes limb girdles
b Includes the ulna 2, rib 2, sacrum 2, fi bula 2, scapula 1, lumber spine 1
c Includes dedifferentiated chondrosarcoma 1, mesenchymal chondrosarcoma 1, angiosarcoma 1, parosteal osteosarcoma 1, fi brosarcoma 1, 
leiomyosarcoma 1
d Includes leiomyosarcoma 2, primitive neuroectodermal tumor 2, clear cell sarcoma 2, epithelioid sarcoma 2, postradiation sarcoma (MFH) 1, 
alveolar soft-part sarcoma 1, extraskeletal osteosarcoma 1, malignant rhabdoid tumor 1, undifferentiated sarcoma 1
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patients, with ages ranging from 4 to 75 years (median 
25 years). The location of the primary bone tumors were 
the femur in 32 patients, tibia in 19, pelvis in 11, humerus 
in 5, and other bones in 10; the soft tissue sarcomas were 
located in the lower extremity in 35, trunk in 8, and 
upper extremity in 5. Altogether, 104 patients had local-
ized disease, and the other 21 (16.8%) had distant 
metastasis at presentation.
Histological types among the bone tumors included 
osteosarcoma in 53 patients, Ewing’s sarcoma in 11, 
malignant fi brous histiocytoma (MFH) in 4, postradia-
tion sarcoma in 3, and others in 6. Histological types 
of soft tissue sarcoma included MFH in 11, liposarcoma 
in 7, synovial sarcoma in 6, rhabdomyosarcoma in 5, 
malignant peripheral nerve sheath tumor (MPNST) in 
3, extraskeletal chondrosarcoma in 3, and others in 13. 
All but eight patients received preoperative and post-
operative neoadjuvant chemotherapy and subsequently 
underwent defi nitive surgery with/or without radiation 
therapy. The eight exceptions had metastatic disease 
at presentation (four with bone tumors, four with soft 
tissue sarcoma). One patient with localized rhabdo-
myosarcoma in the groin had a complete response to 
the induction chemotherapy. The neoadjuvant chemo-
therapy regimens are listed in Table 2.
Radiographic response evaluation of preoperative 
chemotherapy
To evaluate the response to preoperative chemotherapy 
radiographically, we have used the JOA criteria pro-
vided by the JOA Committee on Musculoskeletal 
Tumors, which was accordingly modifi ed from the 
WHO/RECIST evaluation criteria (Table 3).7,8 These 
evaluation criteria are all fundamentally based on the 
radiographically determined change in size of the 
primary tumor from before to after chemotherapy 
estimated by computed tomography (CT) and/or 
magnetic resonance imaging (MRI) with contrast 
enhancement.
All patients were evaluated radiographically for the 
response to preoperative chemotherapy according to 
the criteria defi ned as follows: complete response (CR), 
disappearance of the extraosseous mass lesion con-
tinued for ≥3 weeks; partial response (PR), ≥30% reduc-
tion of the extraosseous mass continued for ≥3 weeks; 
no change (NC), from 10% expansion to <30% reduc-
tion of extraosseous mass continued for ≥3 weeks; pro-
gressive disease (PD), >10% expansion of extraosseous 
mass or other lesions newly emerged in the case of 
either bone tumors and soft tissue sarcomas; CR, disap-
pearance of primary tumor continued for ≥4 weeks; PR, 
≥50% reduction in the size of the primary tumor (two-
dimensional) or ≥30% reduction (one-dimensional) 
continued for ≥4 weeks; NC, from 25% (two-
dimensional) or 10% (one-dimensional) expansion of 
the primary tumor to <50% (two-dimensional) or 30% 
(one-dimensional) reduction of the primary tumor con-
tinued for ≥4 weeks; PD, >25% (two-dimensional) or 
10% (one-dimensional) expansion of the primary tumor 
or other lesions newly emerged. The lesions with PR 
lasting <4 weeks or with 25%–50% reduction in size 
continued ≥4 weeks were separately estimated as a 
minor response (MR) in cases of soft tissue sarcoma. 
The radiographic response to preoperative chemother-
apy should be evaluated more than 4 weeks after the 
end of the treatment, as originally defi ned in the WHO/
RECIST criteria. The JOA criteria adopt the same 
interval of ≥4 weeks for soft tissue sarcomas. For bone 
tumors, however, the defi nitive surgery for primary 
tumors is generally performed within 3 weeks following 
Table 2. Neoadjuvant chemotherapy regimens (n = 125)
Disease No.
Bone tumors (n = 77), osteosarcoma (n = 53)
 ADR/CDDP/MTX 10a
 ADR/CDDP/IFO 8
 CDDP/MTX 5
 ADR/CDDP 4
 ADR/CDDP/IFO/MTX 3
 NECO95J 10
 NECO93J 4
 Others 9a
Ewing’s sarcoma (n = 11)
 VAdrC/IFO 5b
 VAdrC/IE/ICE 3
 EVAIA 1
 VAC/IE 1
 VAIA + cyclosporin 1
Others (n = 13)
 ADR/CDDP 3
 ADR/CDDP/MTX 2
 Others 8c
Soft tissue sarcomas (n = 48)
 IFO (high-dose) 7
 ADR or THP/CDDP/IFO 6
 ADR or THP/CDDP 4
 MAID 4
 CDDP/THP/IFO/ETP 4d
 K3 protocol 4d
 ADR/IFO 3
 Others 16d
ADR, adriamycin; CDDP, cisplatin; MTX, methotrexate; IFO, ifos-
famide; NECO93J/95J, multiinstitutional study of neoadjuvant che-
motherapy using MTX/ADR/CDDP with/or without IFO for 
osteosarcoma in Japan; VAdrC, vincristine (VCR) + ADR + cyclo-
phosphamide (CPA); IE, IFO + etoposide (ETP); ICE, IFO + carbo-
platin (CBDCA) + ETP; EVAIA, ETP + VCR + ADR + IFO + 
actinomycin D (ACD); VAC, VCR + ACD + CPA; VAIA, VCR + 
ADR + IFO + ACD; THP, pirarubicin; MAID, mesna + ADR + IFO 
+ dacarbazine (DTIC); K3 protocol: chemotherapy regimen originally 
used in Kanazawa University
a–d Combined with caffeine in a seven cases, b one case, c two cases, and 
d nine cases
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the completion of preoperative chemotherapy. Conse-
quently, the JOA evaluation criteria modifi ed the 
interval from ≥4 weeks to ≥3 weeks to estimate the 
radiographic response to preoperative chemotherapy 
for bone tumors, and we accordingly use these modifi ed 
criteria in Japan.
Statistical analysis
Overall survival rates of the patients were estimated by 
the method of Kaplan and Meier and were calculated 
from the date of the initial treatment (start of preopera-
tive chemotherapy). A terminal point of overall survival 
was defi ned as the date of the patient’s death from the 
disease or from treatment-related toxicity. Deaths from 
any other concurrent causes were estimated as censored 
data in overall survival. The log-rank test was used 
to evaluate the signifi cance of differences between 
the groups. Two-tailed P < 0.05 was considered statisti-
cally signifi cant in comparison with survival curves. 
These statistical analyses were performed using the 
JMP version 5.01 statistical analysis software package 
for personal computers (SAS Institute, Cary, NC, 
USA).
Results
Radiographic response to preoperative chemotherapy
Table 4 shows the results of the radiographic responses 
to preoperative chemotherapy in 125 patients with bone 
and soft tissue sarcomas. There were 7 cases of CR, 26 
PR, 27 NC, and 17 PD in patients with malignant bone 
tumors and 2 CR, 9 PR, 32 NC (including 9 MR), and 
Table 3. JOA Committee on Musculoskeletal Tumors radiographic response evaluation criteria of preoperative chemotherapy 
for bone and soft tissue sarcomas7,8 modifi ed from the WHO/RECIST criteria for solid cancers9
Malignant bone tumors
 • Subjects: restricted to extraosseously involving lesions
 •  Method: measured by the maximal distance (MD) from the surface of affected bone to the top of extraosseous mass 
lesion on CT and/or MRI images, then estimated by the tumor reduction ratio
  Tumor reduction ratio = (pretreatment MD − posttreatment MD)/(pretreatment MD) × 100 (%)
 • Categories of response evaluation
  CR (complete response) — disappearance of the extraosseous mass lesion continued for ≥3 weeks
  PR (partial response) — at least 30% reduction of the extraosseous mass continued for ≥3 weeks
  NC (no change) — 10% expansion to <30% reduction of the extraosseous mass continued for ≥3 weeks
  PD (progressive disease) — more than 10% expansion of the extraosseous mass or other lesions newly emerged
Soft tissue sarcomas
 • Subjects: all high-grade soft tissue sarcomas treated by neoadjuvant chemotherapy
 •  Methods: estimated bidimensionally or unidimensionally by the change of maximal tumor size before and after 
preoperative chemotherapy using contrast-enhanced CT and/or MRI images.
  Bidimensional measurement
  Tumor reduction ratio =  (pretreatment MTD × VTD) − [posttreatment (MTD × VTD)/pretreatment (MTD × VTD)] × 
100 (%)
  where MTD is the maximum tumor diameter, and VTD is the vertical tumor diameter
  Unidimensional measurement
  Tumor reduction ratio = (pretreatment MTD − posttreatment MTD)/(pretreatment MTD) × 100 (%)
 • Categories of response evaluation
CR — disappearance of primary tumor continued for ≥4 weeks
PR — at least 50% reduction in the size of the primary tumor measured in two dimensions or at least 30% reduction by 
single dimension continued for ≥4 weeks
NC — from 25% (by two dimensions) or 10% (by single dimension) expansion of the primary tumor to <50% (by two 
dimensions) or 30% (by single dimension) reduction of primary tumor continued for ≥4 weeks
PD — more than 25% (by two dimensions) or 10% (by single dimension) expansion of primary tumor or other lesions 
newly emerged
MR (minor response) — lesions with PR effect lasting <4 weeks or with 25%–50% reduction in size continued ≥4 weeks 
were separately estimated as MR in soft tissue sarcomas
Table 4. Results of radiographic response to preoperative 
chemotherapy (n = 125)
Parameter
Malignant bone tumors 
(n = 77)
Soft tissue sarcomas 
(n = 48)
CR 7a 2b
PR 26 9
NC 27 32c
PD 17 5
ORR 33/77 (43%) 11/48 (23%)
ORR, objective response rate (% ratio of the number of CR + PR 
cases)
a Osteosarcoma 2/53 (ORR 4%); Ewing’s sarcoma 4/11 (ORR 36%); 
MFH of bone 1/4 (ORR 25%)
b Rhabdomyosarcoma 2/5 (ORR 40%)
c Including nine minor response cases
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5 PD in those with soft tissue sarcomas. The objective 
response rates (patients with CR or PR/all patients) of 
patients with bone and soft tissue sarcomas were 43% 
(33/77) and 23% (11/48), respectively. The patients with 
CR included four with Ewing’s sarcoma, two with osteo-
sarcoma, one with MFH of bone, and two with soft 
tissue rhabdomyosarcoma.
Correlation of radiographic response with survival in 
malignant bone tumors
Figure 1 shows the overall survival curves according to 
the radiographic response to preoperative chemother-
apy for all patients (n = 77) with malignant bone tumors 
and for 67 patients without metastasis at presentation. 
The radiographic response to preoperative chemother-
apy correlated relatively well with the patients’ overall 
survival (P < 0.0001 for all patients and P = 0.0076 for 
the patients without metastasis at presentation, by log-
rank test), although there seemed to be no prognostic 
correlation between the PR and NC groups.
Figures 2 and 3 show the overall survival curves 
according to the radiographic response to preoperative 
chemotherapy in osteosarcoma patients (n = 53) and 
Ewing’s sarcoma patients (n = 11), respectively. In 
patients with both tumors, the JOA criteria were signifi -
cantly associated with survival, suggesting their clinical 
validity in patients with malignant bone tumors.
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clinical oncology because of its simplicity and easy 
applicability. However, in nonspherical or irregularly 
shaped tumors such as esophageal cancer and malignant 
mesothelioma it is generally diffi cult to evaluate the 
response to chemotherapy accurately using the RECIST 
compared with relatively spherical tumors such as breast 
cancer, lymphoma, and metastatic lung/liver cancers.16 
For these tumors, the RECIST is modifi ed to fi t the 
tumor, or it is even replaced by other biological modali-
ties, such as serum tumor markers or glucose consump-
tion measured by fl uorodeoxyglucose positron emission 
tomography (FDG-PET) scanning to estimate the 
response to chemotherapy.17–20 Interestingly, the tumors 
for which it was diffi cult to evaluate the chemothera-
peutic response correctly by RECIST were reported to 
be nonspherical, irregularly shaped tumors even among 
breast cancers.21 In lymph node and skeletal metastases 
from various cancers (e.g., breast and prostate cancers) 
it is also diffi cult to evaluate the response to chemo-
therapy by a change in tumor size, and skeletal metas-
tases have been primarily excluded from evaluable 
lesions by the RECIST method. Moreover, RECIST 
was originally developed as a tool for screening poten-
tial, new anticancer agents in clinical trials where 
response is the endpoint. RECIST was applied to defi ne 
the clinical response rate, progression rate, and/or time 
to progression quickly, not necessarily to predict 
patients’ prognosis in clinical practice.
With regard to bone and soft tissue sarcomas, the 
response to preoperative chemotherapy as “neo-
adjuvant” is routinely estimated by radiographic 
examinations including CT and/or MRI as well as by 
histopathological evaluation of the extent of tumor 
necrosis (i.e., the ratio of residual viable tumor cells) 
using surgically resected tumor specimens, especially 
(n=48)
1.0
0 9.
NC (including MR)
0.8
0 7.
0.6
va
l
0 5v
i PRCR.
su
r
0.4n
0 3rt
io PD.
po
0.2ro
0 1
p
0 2872 (l k). p= . og-ran
0.0
0 10 20 30 40 50 60 70 80
F ll (M)o ow-up
(n=48)
1.0 CR
0 9. NC
0.8al
0 7vi
v
0 6
.
ur MR.s
0.5on
0 4r
ti
PR.
po PD0.3ro
0 2
p
.
0 3971 (l k)0.1 p= . og-ran
0 0.
0 10 20 30 40 50 60 70 80
Follow-up (M)A B
Fig. 4. Overall survival curves according to the radiographic response to preoperative chemotherapy for soft tissue sarcomas 
(n = 48). A CR vs. PR vs. NC vs. PD. B CR vs. PR vs. MR vs. NC vs. PD. MR, minor response
Correlation of radiographic response with survival in 
soft tissue sarcomas
In patients with soft tissue sarcomas (n = 48), the radio-
graphic response to preoperative chemotherapy did not 
signifi cantly correlate with the patients’ survival (Fig. 
4A). When the patients with NC were divided into NC 
and MR, there was also no correlation between the 
response and survival (Fig. 4B). Regarding soft tissue 
sarcomas, the patients with radiographically NC tended 
to have a better long-term survival than those with CR, 
PR, MR, or PD. Furthermore, there was also no sig-
nifi cant association between the JOA criteria and sur-
vival even in patients without metastasis at presentation 
(n = 37) or in patients with soft tissue sarcomas exclud-
ing small round-cell sarcomas (fi ve rhabdomyosarco-
mas and two primitive neuroectodermal tumors) (n = 
41). In the seven patients with small round-cell sarco-
mas, there was no signifi cant correlation between the 
radiographic response and survival because of the small 
number of these patients in the present series (data 
not shown).
Discussion
The response to chemotherapy for solid cancers has 
been traditionally evaluated based on the radiographic 
change in tumor size before and after treatment. The 
WHO evaluation criteria were simplifi ed and modifi ed 
in 2000 to RECIST criteria,9 in which only one-
dimensional measurement of the maximum tumor 
diameter in the axial plane of CT and/or MRI is used. 
Until now, the RECIST method has been widely used 
to evaluate the response to chemotherapy in the fi eld of 
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for osteosarcomas10 and Ewing’s sarcoma.11,12 In malig-
nant bone tumors, the JOA criteria are directed only at 
extraosseous lesions, modifying the WHO/RECIST cri-
teria because the radiographic changes induced by che-
motherapy refl ect only the mixture of destructive change 
by tumors and reactive change by surrounding tissues, 
and the affected bone never returns to normal status. 
This modifi cation of the evaluation criteria for malig-
nant bone tumors is similar to that for malignant meso-
thelioma.22 Moreover, in soft tissue sarcomas, the JOA 
criteria discussed here are fundamentally based on the 
WHO/RECIST criteria and note that the necrotic area 
within the tumor after chemotherapy should also be 
interpreted as the effect of chemotherapy when the size 
of the tumor does not change before and after chemo-
therapy. The necrotic area is usually evaluated by gado-
linium-enhanced MRI; however, it is frequently diffi cult 
to estimate clinically the precise area of intratumoral 
necrosis because of its complicated shape and/or distri-
bution within the tumor and to distinguish necrosis 
following chemotherapy from that due to spontaneous 
tumor necrosis.
The present retrospective study has demonstrated 
that the JOA radiographic response evaluation criteria 
of preoperative chemotherapy — modifying the WHO/
RECIST criteria based on the change in tumor size — 
correlate relatively well with the prognosis of patients 
with malignant bone tumors but not with that of patients 
with soft tissue sarcomas. Patients with soft tissue sar-
comas whose disease was labeled radiographically as 
NC (defi ned as SD, or stable disease, in RECIST) 
tended to have better long-term survival than those 
whose disease was labeled CR, PR, MR, or PD. Similar 
results were indicated in patients with gastrointestinal 
stromal tumors (GISTs) by Choi and colleagues.23,24
It has been pointed out that patients with various 
advanced cancers whose disease was estimated not only 
as CR or PR but also as NC/SD were considered to 
be able to have their survival prolonged in clinical trials 
using new molecular targeting agents that exhibited 
cytostatic rather than cytocidal activities on cancer 
cells.25 There are possibly two major reasons for this 
phenomenon in soft tissue sarcomas: (1) Tumor necro-
sis induced by preoperative chemotherapy does not 
necessarily refl ect tumor shrinkage; instead, cystic 
change following tumor necrosis often results in tem-
porary tumor enlargement (Fig. 5). (2) Soft tissue sar-
comas show a relatively slower growing pattern than 
do osteosarcoma and Ewing’s sarcoma; thus, prompt 
tumor reduction in size is not expected only after 
several cycles of preoperative chemotherapy. Indeed, 
we recently treated a 20-year-old woman with a huge 
round-cell liposarcoma in her left leg associated with 
a solitary lung metastasis at presentation. She responded 
to 10 cycles of preoperative chemotherapy using high-
dose ifosfamide (12.0–13.5 g/m2 per cycle with mesna) 
by fi nally being estimated as PR for the primary tumor 
and CR for the lung metastasis (data not shown). The 
discrepancy between the tumor size-based radiographic 
response evaluation criteria and the survival of patients 
with soft tissue sarcomas might be infl uenced by other 
factors, such as using different chemotherapeutic regi-
mens and estimating the effect only by the changes in 
the size of the primary tumor.
The present study has strongly suggested that the 
tumor size-based radiographic response evaluation 
criteria for preoperative chemotherapy do not predict 
survival for patients with soft tissue sarcomas. Thus, we 
need to search for a more sensitive and specifi c evalua-
tion method, such as FDG-PET20,26,27 or thallium (201Tl) 
scintigraphy,28,29 rather than the usual strictly size-based 
response evaluation criteria by CT and/or MRI to esti-
mate the effi cacy of newly developed chemotherapeutic 
(cytocidal) and molecular-targeting (cytostatic) agents 
for soft tissue sarcomas.
Choi et al. recently proposed novel response evalua-
tion criteria for molecular-targeted anticancer drugs 
using a combination of reduced tumor size and decreased 
density on contrast-enhanced CT through their experi-
ences in clinical trials of imatinib mesylate (Gleevec) 
for patients with GIST.23,24 Furthermore, several studies 
have suggested the usefulness of FDG-PET to estimate 
the response to preoperative chemotherapy in patients 
with osteosarcoma and Ewing’s sarcoma.26,27 However, 
FDG-PET has some limitations for evaluating tumor 
response to treatment, such as specifi city, access, cost, 
and quantitative measurements; and at present it is not 
used universally to assess the response of various malig-
nant tumors including GIST.
We plan to investigate a new method to evaluate the 
three-dimensional (3D) volumetric change of intratu-
moral necrosis, measured by density/intensity change 
on 3D-CT/or MRI scans. We think it may be a more 
sensitive, more specifi c modality for assessing the 
response of bone and soft tissue sarcomas to chemo-
therapy than the traditional but somewhat outdated 
size-based response evaluation criteria such as 
RECIST.
Conclusion
The JOA radiographic response evaluation criteria of 
preoperative chemotherapy based on the change of 
primary tumor size is valid for malignant bone tumors 
but invalid for soft tissue sarcomas. Other evaluation 
modalities to assess the response to preoperative 
chemotherapy using innovative functional imaging 
techniques, such as FDG-PET and contrast-enhanced 
3D-CT/MRI, are needed for soft tissue sarcomas.
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Fig. 5. A 43-year-old man had a poorly differentiated synovial 
sarcoma in his right upper arm. A Magnetic resonance imaging 
(MRI) at his initial presentation. B MRI after four cycles of 
preoperative chemotherapy. There was marked cystic change 
in the tumor but no reduction in tumor size. C Fluorodeoxy-
glucose positron emission tomography (FDG-PET) at the 
initial presentation, showing abnormally hot uptake at the 
tumor. D FDG-PET after four cycles of preoperative chemo-
therapy showed disappearance of glucose uptake in the tumor. 
E Histology at biopsy (H&E). F Surgically resected specimen 
after preoperative chemotherapy, confi rming the marked 
cystic change and only minimal residual viable tumor cells 
along the cyst wall (arrow)
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